Business Description
Enanta Pharmaceuticals Inc
NAICS : 325412
SIC : 2835
ISIN : US29251M1062
Description
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.47 | |||||
| Equity-to-Asset | 0.34 | |||||
| Debt-to-Equity | 0.43 | |||||
| Debt-to-EBITDA | -0.53 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -0.86 | |||||
| Beneish M-Score | -3.12 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -12.7 | |||||
| 3-Year EBITDA Growth Rate | 1.5 | |||||
| 3-Year EPS without NRI Growth Rate | -11.8 | |||||
| 3-Year FCF Growth Rate | -9.2 | |||||
| 3-Year Book Growth Rate | -32.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 20.27 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 20.23 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 16.25 | |||||
| 9-Day RSI | 20.11 | |||||
| 14-Day RSI | 22.73 | |||||
| 3-1 Month Momentum % | -16.09 | |||||
| 6-1 Month Momentum % | -22.34 | |||||
| 12-1 Month Momentum % | 7.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.21 | |||||
| Quick Ratio | 5.21 | |||||
| Cash Ratio | 4.31 | |||||
| Days Sales Outstanding | 42.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.6 | |||||
| Shareholder Yield % | -13.31 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -179.92 | |||||
| Net Margin % | -171.58 | |||||
| FCF Margin % | -142.99 | |||||
| ROE % | -68.06 | |||||
| ROA % | -27.9 | |||||
| ROIC % | -115.49 | |||||
| 3-Year ROIIC % | 78.81 | |||||
| ROC (Joel Greenblatt) % | -200.72 | |||||
| ROCE % | -29.94 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.97 | |||||
| PB Ratio | 1.03 | |||||
| Price-to-Tangible-Book | 1.03 | |||||
| EV-to-EBIT | 0.56 | |||||
| EV-to-EBITDA | 0.57 | |||||
| EV-to-Revenue | -0.88 | |||||
| EV-to-Forward-Revenue | 0.12 | |||||
| EV-to-FCF | 0.61 | |||||
| Price-to-GF-Value | 0.27 | |||||
| Price-to-Median-PS-Value | 0.26 | |||||
| Price-to-Net-Current-Asset-Value | 2.46 | |||||
| Price-to-Net-Cash | 301.5 | |||||
| Earnings Yield (Greenblatt) % | 178.57 | |||||
| FCF Yield % | -72.55 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ENTA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Enanta Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 67.635 | ||
| EPS (TTM) ($) | -5.48 | ||
| Beta | 0.46 | ||
| 3-Year Sharpe Ratio | -1.05 | ||
| 3-Year Sortino Ratio | -1.2 | ||
| Volatility % | 62.27 | ||
| 14-Day RSI | 22.73 | ||
| 14-Day ATR ($) | 0.738549 | ||
| 20-Day SMA ($) | 8.501 | ||
| 12-1 Month Momentum % | 7.53 | ||
| 52-Week Range ($) | 6.25 - 17.8 | ||
| Shares Outstanding (Mil) | 21.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Enanta Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Enanta Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Enanta Pharmaceuticals Inc Frequently Asked Questions
What is Enanta Pharmaceuticals Inc(ENTA)'s stock price today?
The current price of ENTA is $6.03. The 52 week high of ENTA is $17.80 and 52 week low is $6.25.
When is next earnings date of Enanta Pharmaceuticals Inc(ENTA)?
The next earnings date of Enanta Pharmaceuticals Inc(ENTA) is 2025-02-07 Est..
Does Enanta Pharmaceuticals Inc(ENTA) pay dividends? If so, how much?
Enanta Pharmaceuticals Inc(ENTA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers